Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. (2017)

First Author: Weber J
Attributed to:  MICA: Immunotherapy for oral cancer prevention and treatment funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1709030

PubMed Identifier: 28891423

Publication URI: http://europepmc.org/abstract/MED/28891423

Type: Journal Article/Review

Volume: 377

Parent Publication: The New England journal of medicine

Issue: 19

ISSN: 0028-4793